THE TGA has registered Mounjaro (tirzepatide) as the first dual-action GLP-1 and GIP receptor co-agonist for chronic weight management in obesity and overweight patients.
Available by private prescription, Mounjaro is approved for adults with a BMI of 30 kg/m or higher or those with a BMI of 27-30 kg/m with a weight-related condition like hypertension, cardiovascular disease, sleep aponea, prediabetes or type 2 diabetes mellitus.
A/Prof Samantha Hocking from the Charles Perkins Centre, University of Sydney, noted that the drug's approval allows broader patient access to sustained weight loss benefits.
The registration follows the Phase 3 SURMOUNT-1 trial, showing significant weight loss in 96% of participants.
Manufacturer Eli Lilly aims to meet global production targets by increasing supply by 150% in late 2024.
The weight-loss medicine is used as an adjunct to a reduced-calorie diet and increased physical activity.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 24
